BioCryst Pharmaceuticals Names Charlie Gayer as CEO, Appoints Babar Ghias as CFO, and Announces European Orladeyo Business Sale for up to $264 Million.

BioCryst Pharmaceuticals has named Charlie Gayer as its new CEO, replacing Randy Schatzman. The company has also announced the appointment of Babar Ghias as CFO and Babar Ghias as Head of Corporate Development. BioCryst Pharmaceuticals has sold its European Orladeyo business to Neopharmed Gentili for up to $264 million and received approval for Orladeyo in Colombia. The company has also presented new data on the long-term efficacy and safety of Orladeyo across all ages.

BioCryst Pharmaceuticals (NASDAQ: BCRX) has made significant moves in its leadership and business strategy. The company has announced the appointment of Charlie Gayer as the new CEO, effective January 1, 2026, replacing Jon Stonehouse. Gayer, currently the company’s chief commercial officer, will also become president, effective August 1, 2025 [1].

Additionally, BioCryst has appointed Babar Ghias as the new CFO and Head of Corporate Development [1]. The company has also sold its European Orladeyo business to Neopharmed Gentili for up to $264 million [2]. Furthermore, BioCryst received approval for Orladeyo in Colombia and presented new data on the long-term efficacy and safety of Orladeyo across all ages [3].

Gayer's appointment follows a successful tenure at BioCryst, where he played a pivotal role in the commercial launch of ORLADEYO® (berotralstat), a first oral, once-daily plasma kallikrein inhibitor for hereditary angioedema. The company expects peak sales of $1 billion for ORLADEYO [1]. Stonehouse, who will continue to serve on the board, praised Gayer’s leadership and the company’s culture under his guidance.

The sale of the European Orladeyo business is part of BioCryst’s strategic plan to focus on its core strengths and market opportunities. The company has also seen strong growth in its stock price, with recent upgrades from BofA Securities [3].

Overall, these moves indicate BioCryst’s commitment to maintaining its leadership position in the rare disease market and continuing its mission to bring life-changing therapies to patients.

References:
[1] https://seekingalpha.com/news/4475461-biocryst-appoints-charlie-gayer-to-succeed-jon-stonehouse-as-ceo
[2] https://finance.yahoo.com/news/biocryst-announces-charlie-gayer-succeed-110000066.html
[3] https://www.marketwatch.com/investing/stock/bcrx